{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T20:50:11Z","timestamp":1792097411060,"version":"4.4.0"},"reference-count":20,"publisher":"Wiley","issue":"7","license":[{"start":{"date-parts":[[2020,7,9]],"date-time":"2020-07-09T00:00:00Z","timestamp":1594252800000},"content-version":"vor","delay-in-days":8,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Pediatrics International"],"published-print":{"date-parts":[[2020,7]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>This study evaluated the efficacy, safety, and acceptability of a new ferrous sulfate oral solution (Tardyferon\u00ae 20\u00a0mg\/mL) in young children with mild or moderate iron deficiency anemia (IDA).<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>This was a multicenter, national, single\u2010arm, open\u2010label study. Children aged 6\u201353\u00a0months presenting with mild or moderate IDA (i.e.,\u00a0blood hemoglobin (Hb) ranging from\u00a07.0\u00a0to\u00a010.9\u00a0g\/dL and serum ferritin &lt;12\u00a0ng\/mL) were eligible for inclusion. The ferrous sulfate heptahydrate solution (2\u00a0mg\/kg\/day) was administered orally for 3\u00a0months. If normalization of either Hb or ferritin was not achieved at month\u00a03 the treatment was continued for another 3\u00a0months.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Of the 100 children screened, 21 aged 6\u201317\u00a0months were included and received the study treatment, and 19 were analyzed for hematologic outcomes at month\u00a03. Only one patient continued treatment for the additional 3\u00a0months. At month\u00a03, mean \u00b1 SD Hb and ferritin levels were 12.0 \u00b1 0.7\u00a0g\/dL and 31.5 \u00b1 19.4\u00a0ng\/mL, respectively. Hemoglobin and ferritin levels were normalized in 95% (18\/19) and 84% (16\/19) of the patients, respectively. Treatment compliance and levels of satisfaction of both the parents and the investigators were high. Overall, 33.3% of patients (7\/21) experienced at least one adverse event. Only one patient (4.8%) experienced a drug\u2010related adverse event (upper abdominal pain).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>A 2\u00a0mg\/kg daily dose of the new oral ferrous sulfate heptahydrate solution provides substantial therapeutic benefit with high levels of tolerability in young children who have mild or moderate IDA.<\/jats:p><\/jats:sec>","DOI":"10.1111\/ped.14237","type":"journal-article","created":{"date-parts":[[2020,3,19]],"date-time":"2020-03-19T16:11:45Z","timestamp":1584634305000},"page":"820-827","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Ferrous sulfate oral solution in young children with iron deficiency anemia: An open\u2010label trial of efficacy, safety, and acceptability"],"prefix":"10.1111","volume":"62","author":[{"given":"Lidia","family":"Pachuta W\u0119gier","sequence":"first","affiliation":[{"name":"Lidia Pachuta W\u0119gier Medical Services Lublin Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maciej","family":"Kubiak","sequence":"additional","affiliation":[{"name":"Tolek Clinic for Children Lesznowola Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Agata","family":"Liebert","sequence":"additional","affiliation":[{"name":"Tolek Clinic for Children Lesznowola Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thierry","family":"Clavel","sequence":"additional","affiliation":[{"name":"TCC Consulting Revel France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Agn\u00e8s","family":"Montagne","sequence":"additional","affiliation":[{"name":"Clinical Development Department Institut de Recherche Pierre Fabre CRDPF Toulouse France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aline","family":"Stennevin","sequence":"additional","affiliation":[{"name":"Clinical Development Department Institut de Recherche Pierre Fabre CRDPF Toulouse France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandrine","family":"Roye","sequence":"additional","affiliation":[{"name":"Clinical Development Department Institut de Recherche Pierre Fabre CRDPF Toulouse France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0527-9816","authenticated-orcid":false,"given":"Asmaa","family":"Boudribila","sequence":"additional","affiliation":[{"name":"Clinical Development Department Institut de Recherche Pierre Fabre CRDPF Toulouse France"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2020,7,9]]},"reference":[{"key":"e_1_2_8_2_1","first-page":"1","volume-title":"Iron Deficiency Anaemia: Assessment, Prevention and Control","author":"WHO","year":"2001"},{"key":"e_1_2_8_3_1","first-page":"1","volume-title":"The Global Prevalence of Anaemia in 2011","author":"WHO","year":"2015"},{"key":"e_1_2_8_4_1","unstructured":"International Nutritional Anemia Consultative Group (INACG) WHOW United Nations Children\u2019s Fund (UNICEF) StoltzfusRJ DreyfussMLEditors.Guidelines for the Use of Iron Supplements to Prevent and Treat Iron Deficiency Anemia.Washington DC:ILSI.1998 updated in 2003.https:\/\/ilsirf.org\/wpcontent\/uploads\/sites\/5\/2016\/06\/iron_guidelines_revised2003.pdf[Cited 6 August 2019]."},{"key":"e_1_2_8_5_1","volume-title":"Iron\u2010Deficiency Anemia in Children","author":"Abdullah K","year":"2013"},{"key":"e_1_2_8_6_1","doi-asserted-by":"publisher","DOI":"10.5045\/br.2016.51.4.268"},{"key":"e_1_2_8_7_1","first-page":"1","volume-title":"Iron and Iron Salts. Drugs Acting on the Blood and the Blood Forming Organs","author":"Hillman R","year":"2006"},{"key":"e_1_2_8_8_1","volume-title":"Model List of Essential Medicines for Children","author":"WHO","year":"2019"},{"key":"e_1_2_8_9_1","volume-title":"Model List of Essential Medicines","author":"WHO","year":"2019"},{"key":"e_1_2_8_10_1","volume-title":"Haemoglobin Concentrations for the Diagnosis of Anaemia and Assessment of Severity","author":"WHO","year":"2011"},{"key":"e_1_2_8_11_1","volume-title":"Serum Ferritin Concentrations for the Assessment of Iron Status and Iron Deficiency in Populations","author":"WHO","year":"2011"},{"key":"e_1_2_8_12_1","doi-asserted-by":"publisher","DOI":"10.1590\/S1516-31802008000600004"},{"key":"e_1_2_8_13_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00394-011-0210-7"},{"key":"e_1_2_8_14_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10995-012-0981-3"},{"key":"e_1_2_8_15_1","doi-asserted-by":"publisher","DOI":"10.1177\/156482650602700304"},{"key":"e_1_2_8_16_1","doi-asserted-by":"publisher","DOI":"10.1080\/08880010490457114"},{"key":"e_1_2_8_17_1","first-page":"203","article-title":"A randomized placebo\u2010controlled trial of iron supplementation in breastfed young infants initiated on complementary feeding: effect on haematological status","volume":"22","author":"Nagpal J","year":"2004","journal-title":"J. Health Popul. Nutr."},{"key":"e_1_2_8_18_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.mpg.0000243440.85452.38"},{"key":"e_1_2_8_19_1","doi-asserted-by":"publisher","DOI":"10.1093\/ajcn\/58.3.339"},{"key":"e_1_2_8_20_1","doi-asserted-by":"publisher","DOI":"10.1542\/peds.108.3.613"},{"key":"e_1_2_8_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2214-109X(13)70046-9"}],"container-title":["Pediatrics International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fped.14237","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/ped.14237","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/ped.14237","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/ped.14237","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,25]],"date-time":"2023-08-25T21:00:32Z","timestamp":1692997232000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/ped.14237"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,7]]},"references-count":20,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2020,7]]}},"alternative-id":["10.1111\/ped.14237"],"URL":"https:\/\/doi.org\/10.1111\/ped.14237","archive":["Portico"],"relation":{},"ISSN":["1328-8067","1442-200X"],"issn-type":[{"value":"1328-8067","type":"print"},{"value":"1442-200X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,7]]},"assertion":[{"value":"2019-08-07","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-03-16","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-07-09","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}